Nothing Special   »   [go: up one dir, main page]

AP2002002454A0 - Agents for reversal of drug resistance in mycobacterium tuberculosis. - Google Patents

Agents for reversal of drug resistance in mycobacterium tuberculosis.

Info

Publication number
AP2002002454A0
AP2002002454A0 APAP/P/2002/002454A AP2002002454A AP2002002454A0 AP 2002002454 A0 AP2002002454 A0 AP 2002002454A0 AP 2002002454 A AP2002002454 A AP 2002002454A AP 2002002454 A0 AP2002002454 A0 AP 2002002454A0
Authority
AP
ARIPO
Prior art keywords
inh
resistance
isoniazid
present
strains
Prior art date
Application number
APAP/P/2002/002454A
Inventor
Bakulesh Mafatlal Khamar
Original Assignee
Bakulesh Mafatlal Khamar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bakulesh Mafatlal Khamar filed Critical Bakulesh Mafatlal Khamar
Publication of AP2002002454A0 publication Critical patent/AP2002002454A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Multidrug resistance to anti-tuberculous drugs poses threat in the treatment of tuberculosis. These strains are resistant to at least two first line anti-tuberculous drugs such as inh and rifampicin. Frequently, such mdr strains show resistance to all commonly used first-lne agent i.E inh, rifamcpin, streptomycin, ethambutol and pyrazinamide.ISoniazid is the most widely usedanti-tubeculous drug. Resistance to isoniazid can occur by increased expression in inha or by mutations that lower the enzyme's affinity to nadh. Mutations in katg, which encodes catalayse peroxidase, is the most comon source of resistance. Another mechanism of isoniazid resistance occurs by defects in nadh dehydrogenase (ndh)of the resipiratory chain. Increases expression of aphc has been suggested as another mechanism of inh resistance in mycobacteria. The present invention overcomes inh resistance by the use of penicillins with inh. According to present invention, penicillins when used in effective amount, reduces the mic of inh in multi-drug resistant strains of m. Tuberculosis. The improved inh sensitivity, as brought by the present invention, falls within the range which can be exploited for efective therapeutic intrvention.
APAP/P/2002/002454A 2000-06-28 2001-06-26 Agents for reversal of drug resistance in mycobacterium tuberculosis. AP2002002454A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN597MU2000 2000-06-28
PCT/IB2001/001136 WO2002000165A2 (en) 2000-06-28 2001-06-26 Agent for reversal of drug resistance in mycobacterium tuberculosis

Publications (1)

Publication Number Publication Date
AP2002002454A0 true AP2002002454A0 (en) 2002-06-30

Family

ID=11097261

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2002/002454A AP2002002454A0 (en) 2000-06-28 2001-06-26 Agents for reversal of drug resistance in mycobacterium tuberculosis.

Country Status (4)

Country Link
AP (1) AP2002002454A0 (en)
AU (1) AU6625701A (en)
EA (1) EA004875B1 (en)
WO (1) WO2002000165A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
WO2004089421A2 (en) 2003-03-31 2004-10-21 Xencor, Inc Methods for rational pegylation of proteins
WO2005056759A2 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
PL2471813T3 (en) 2004-07-15 2015-09-30 Xencor Inc Optimized Fc variants
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP2314618A3 (en) 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
BR122021010656B1 (en) 2007-12-26 2022-07-19 Xencor, Inc ANTI-TNF ANTIBODY AND PHARMACEUTICAL COMPOSITION
CN101810610B (en) * 2010-04-19 2012-09-26 海南美兰史克制药有限公司 Amoxicillin sodium flucloxacillin sodium medicine compound liposome injection
WO2013096948A1 (en) 2011-12-23 2013-06-27 Lydon Nicholas B Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
CN109385439A (en) * 2018-09-18 2019-02-26 上海晶诺生物科技有限公司 The one recombination TM4 phage library and its application for constructing nadh dehydrogenase gene family missing mycobacterium tuberculosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871912A (en) * 1992-04-30 1999-02-16 Institut Pasteur Nucleic acid probes, sequences and methods for detecting mycobacterium tuberculosis resistant to isoniazid
US5851763A (en) * 1992-09-17 1998-12-22 Institut Pasteur Rapid detection of antibiotic resistance in mycobacterium tuberculosis
US5633131A (en) * 1992-04-30 1997-05-27 Institut Pasteur Rapid detection of isoniazid resistance in mycobacterium tuberculosis probes for selecting nucleic acid encoding isoniazid resistance, and methods and kits
US5686590A (en) * 1993-05-14 1997-11-11 Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. Methods and compositions for detecting and treating mycobacterial infections using an INHA gene
WO1995033851A2 (en) * 1994-06-09 1995-12-14 Innogenetics N.V. Method for the detection of the antibiotic resistance spectrum of mycobacterium species
US6200754B1 (en) * 1998-03-19 2001-03-13 Variagenics, Inc. Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes

Also Published As

Publication number Publication date
WO2002000165A3 (en) 2002-06-20
WO2002000165A2 (en) 2002-01-03
EA004875B1 (en) 2004-08-26
AU6625701A (en) 2002-01-08
EA200200290A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
AP2002002454A0 (en) Agents for reversal of drug resistance in mycobacterium tuberculosis.
Sisson et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori
Fradin et al. Oral cyclosporine for severe chronic idiopathic urticaria and angioedema
MA29378B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-CARBOXYARYL-SUBSTITUTED DIPHENYLUREE FOR THE TREATMENT OF CANCER
BRPI0409125A (en) combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
IS2923B (en) Methods for the Treatment or Prevention of 2,4-Pyrimidinediamine Compounds of Autoimmune Diseases
WO2000066138A3 (en) Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
HUP9802721A1 (en) Method and composition for the treatment and prevention of hyperuricemia
Korner et al. Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia
MX2009000418A (en) Anti-cocaine compositions and treatment.
Almeida et al. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis
HUP9802355A2 (en) Powder-metallurgy produced high-speed steel
BR0107801A (en) Process for treating slag or slag mixtures
WO2002000163A3 (en) The method of treating drug resistant mycobacterium tuberculosis infection
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
Edling Interaction between drugs and solvents as a cause of fatty change in the liver?
Galvan et al. Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle
Darblade et al. Piboserod (SB 207266), a selective 5-HT 4 receptor antagonist, reduces serotonin potentiation of neurally-mediated contractile responses of human detrusor muscle
Lawrence et al. Effect of BQ-123 and Ro 47-0203 (bosentan) on endothelin-induced vasoconstriction in the rat skin
KR890001666A (en) Sliding Gate Nozzle for Special Steels
Pfeiffer The pharmacology of mesulergine
Hudu An overview of the pattern of first-and second-line anti-tuberculosis drug resistance gene mutations
Vehovar et al. The corrosion behavior of electrode surfaces enriched with silicon in silicon bearing cast steel
Ramachandran et al. Effect of rifampicin and isoniazid on cytochrome P-450 in mycobacteria
Zhou et al. Immunosuppressive Effects of Triptonide on Allergic Contact Dermatitis in Mice and the Study of its Mechanism